Comprehensive molecular analysis of genomic profiles and PD-L1 expression in lung adenocarcinoma with a high-grade fetal adenocarcinoma component.

CTNNB1 High-grade fetal adenocarcinoma KMT2C programmed death ligand-1 (PD-L1) whole-exome sequencing (WES)

Journal

Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875

Informations de publication

Date de publication:
Mar 2021
Historique:
entrez: 23 4 2021
pubmed: 24 4 2021
medline: 24 4 2021
Statut: ppublish

Résumé

Fetal adenocarcinoma of the lung is a rare variant of lung adenocarcinoma and is subcategorized into low-grade and high-grade (H-FLAC) fetal adenocarcinoma. We previously reported poor prognosis in pulmonary adenocarcinomas with an H-FLAC component; however, the genetic abnormalities involved in H-FLAC remain unclear. Therefore, this study aimed to elucidate molecular abnormalities as potential therapeutic targets for H-FLACs. We performed immunohistochemical analysis and comprehensive genetic analyses using whole-exome sequencing in 16 lung cancer samples with an H-FLAC component. DNA was extracted from formalin-fixed paraffin-embedded tissues after macrodissection of the H-FLAC component. Cancer-related mutations were identified in This study indicates that lung cancers with an H-FLAC component rarely harbor currently targetable driver gene mutations for lung cancer but display a high frequency of

Sections du résumé

BACKGROUND BACKGROUND
Fetal adenocarcinoma of the lung is a rare variant of lung adenocarcinoma and is subcategorized into low-grade and high-grade (H-FLAC) fetal adenocarcinoma. We previously reported poor prognosis in pulmonary adenocarcinomas with an H-FLAC component; however, the genetic abnormalities involved in H-FLAC remain unclear. Therefore, this study aimed to elucidate molecular abnormalities as potential therapeutic targets for H-FLACs.
METHODS METHODS
We performed immunohistochemical analysis and comprehensive genetic analyses using whole-exome sequencing in 16 lung cancer samples with an H-FLAC component. DNA was extracted from formalin-fixed paraffin-embedded tissues after macrodissection of the H-FLAC component.
RESULTS RESULTS
Cancer-related mutations were identified in
CONCLUSIONS CONCLUSIONS
This study indicates that lung cancers with an H-FLAC component rarely harbor currently targetable driver gene mutations for lung cancer but display a high frequency of

Identifiants

DOI: 10.21037/tlcr-20-1158 PMID: 33889510 PMC: PMC8044470
pubmed: 33889510
doi: 10.21037/tlcr-20-1158
pii: tlcr-10-03-1292
pmc: PMC8044470
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1292-1304

Informations de copyright

2021 Translational Lung Cancer Research. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr-20-1158). Dr. SM reports other from Fujitsu Laboratories, Ltd., other from Liquid Mine, Ltd., outside the submitted work. The other authors have no conflicts of interest to declare.

Références

Mod Pathol. 2002 Jun;15(6):617-24
pubmed: 12065775
J Thorac Oncol. 2016 Nov;11(11):1976-1983
pubmed: 27374456
Diagn Cytopathol. 2007 Jan;35(1):39-42
pubmed: 17173289
Lung Cancer. 2013 Sep;81(3):371-376
pubmed: 23891509
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
J Clin Oncol. 2005 Apr 10;23(11):2513-20
pubmed: 15738541
Lung Cancer. 2013 Jan;79(1):8-13
pubmed: 23098378
Jpn J Thorac Cardiovasc Surg. 2006 Dec;54(12):539-42
pubmed: 17236658
Mod Pathol. 2020 Jan;33(1):109-117
pubmed: 31383957
J Thorac Oncol. 2015 Sep;10(9):1240-1242
pubmed: 26291007
Nat Med. 2016 Nov;22(11):1342-1350
pubmed: 27694933
J Thorac Oncol. 2013 Jan;8(1):52-61
pubmed: 23242438
Mol Cell Biol. 2013 Dec;33(23):4745-54
pubmed: 24081332
Am J Surg Pathol. 1998 Apr;22(4):399-411
pubmed: 9537466
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
J Thorac Oncol. 2009 Jan;4(1):22-9
pubmed: 19096302
Thorac Cancer. 2020 Jun;11(6):1703-1707
pubmed: 32227456
Nat Biotechnol. 2016 Feb;34(2):155-63
pubmed: 26619011
Histopathology. 2015 Dec;67(6):806-16
pubmed: 25851923
Surg Case Rep. 2018 Jul 4;4(1):70
pubmed: 29974291
Nature. 2019 Nov;575(7781):217-223
pubmed: 31666701
Carcinogenesis. 2012 Jul;33(7):1270-6
pubmed: 22510280
Jpn J Clin Oncol. 2006 Feb;36(2):69-75
pubmed: 16449241
Mod Pathol. 2011 May;24(5):653-64
pubmed: 21252858
Cancer Discov. 2020 Jan;10(1):54-71
pubmed: 31658955
J Thorac Dis. 2017 Jul;9(7):2071-2078
pubmed: 28840008
J Clin Oncol. 2012 May 1;30(13):1438-46
pubmed: 22393100
Hum Pathol. 2019 Aug;90:54-59
pubmed: 31121194
JCO Precis Oncol. 2018 Nov;2:1-24
pubmed: 35135139
Genome Med. 2018 Apr 25;10(1):33
pubmed: 29695279
J Thorac Oncol. 2011 Feb;6(2):244-85
pubmed: 21252716
Am J Surg Pathol. 2013 Jun;37(6):924-32
pubmed: 23629442
Med Oncol. 2013;30(3):645
pubmed: 23797772
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Mod Pathol. 2018 Sep;31(9):1404-1417
pubmed: 29785018
Cold Spring Harb Perspect Med. 2016 Nov 1;6(11):
pubmed: 27638352
Int J Clin Exp Pathol. 2019 Mar 01;12(3):774-786
pubmed: 31933885

Auteurs

Masaki Suzuki (M)

Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan.

Rika Kasajima (R)

Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Division of Health Medical Intelligence, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Tomoyuki Yokose (T)

Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan.

Hiroyuki Ito (H)

Department of Thoracic Surgery, Kanagawa Cancer Center, Yokohama, Japan.

Eigo Shimizu (E)

Division of Health Medical Intelligence, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Seira Hatakeyama (S)

Division of Clinical Genome Research, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Kazuaki Yokoyama (K)

Department of Hematology/Oncology, Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Rui Yamaguchi (R)

Division of Health Medical Intelligence, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Division of Cancer Systems Biology, Aichi Cancer Center Research Institute, Nagoya, Japan.
Division of Cancer Informatics, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Yoichi Furukawa (Y)

Division of Clinical Genome Research, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Satoru Miyano (S)

Division of Health Medical Intelligence, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Department of Integrated Data Science, Medical and Dental Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan.

Seiya Imoto (S)

Division of Health Medical Intelligence, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Emi Yoshioka (E)

Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan.

Kota Washimi (K)

Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan.

Yoichiro Okubo (Y)

Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan.

Kae Kawachi (K)

Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan.

Shinya Sato (S)

Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan.

Yohei Miyagi (Y)

Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan.

Classifications MeSH